<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04062981</url>
  </required_header>
  <id_info>
    <org_study_id>YKP509C002</org_study_id>
    <nct_id>NCT04062981</nct_id>
  </id_info>
  <brief_title>Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome</brief_title>
  <official_title>Phase 1, Open-Label Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label extension study from YKP509C001 to evaluate the safety and tolerability of
      carisbamate in subjects with Lennox-Gastaut Syndrome (LGS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who successfully completed the YKP509C001 study and could benefit from continued
      exposure to carisbamate.

      This is an open-label (OL), multi-center study of carisbamate in subjects with LGS, with
      safety assessments from Baseline (Visit 1) through the early termination (ET)/end of study
      (EOS) visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-Label (OL), multi-center study of carisbamate in subjects with LGS, with safety assessments from Baseline (Visit 1) through early termination (ET)/end of study (EOS) visit</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concomitant medication</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead electrocardiograms (ECGs)</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examinations</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seizure Frequency</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>An assessment of seizure frequency will be made using a subject/caregiver seizure diary with seizure type and number of daily seizures recorded since the prior visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety- adverse events</measure>
    <time_frame>The duration of this OL study will be until carisbamate bas been approved for treatment of LGS and is available by prescription, or development of carisbamate for LGS has stopped, whichever is first. This could occur up to 36 months.</time_frame>
    <description>Adverse events assessment for seriousness (yes, no) severity (mild, moderate, severe), affect on carisbamate dosing (increase,reduced, interrupted, withdrawn, no change) and outcome (recovered/resolved, recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, fatal or unknown</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lennox Gastaut Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects â‰¥ 18 years of age
These subjects will reach maximum stable dose and continue onto YKP509C002.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 12 to &lt;18 years of age
These subjects will reach maximum stable dose and continue onto YKP509C002.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 6 to &lt;12 years of age
These subjects will reach maximum stable dose and continue onto YKP509C002.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 2 to &lt;6 years of age
These subjects will reach maximum stable dose and continue onto YKP509C002.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carisbamate</intervention_name>
    <description>An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)</description>
    <arm_group_label>Cohort I</arm_group_label>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_label>Cohort III</arm_group_label>
    <arm_group_label>Cohort IV</arm_group_label>
    <other_name>YKP509</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who completed the YKP509C001 study

          -  Investigator believes subject could benefit from continued exposure to study drug

          -  Subjects must continue to meet all of the inclusion criteria from the YKP509C001 study

        Exclusion Criteria:

          -  Subjects must continue to not meet any of the exclusion criteria from the YKP509C001
             study

          -  There are no additional exclusion criteria in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ry R Forseth, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SK Life Science, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ry R Forseth, Ph.D.</last_name>
    <phone>201-509-4686</phone>
    <email>rforseth@sklsi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Yi Kang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joon Yi Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Morse, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Morse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Roberts, MD</last_name>
    </contact>
    <investigator>
      <last_name>Colin Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Utah School of Medicine - Primary Children's Hospital (Primary Children's Medical Center)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Sweney, MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthew Sweney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UW Valley Medical Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Vossler, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Vossler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lennox Gastaut Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

